medigraphic.com
Instituto Nacional de Salud Pública

2025, Número 1

<< Anterior Siguiente >>

salud publica mex 2025; 67 (1)


Exposición a arsénico inorgánico e hipertensión en mujeres no diabéticas mexicanas

Rangel-Moreno K, López-Carrillo L, Cebrián ME

Idioma: Ingles.
Referencias bibliográficas: 49
Paginas: 20-27
Archivo PDF: 277.23 Kb.


RESUMEN

Objetivo. Evaluar la asociación entre la prevalencia de hipertensión arterial (HTA) y los niveles urinarios de arsénico inorgánico (iAs) y sus metabolitos en mujeres del norte de México sin diabetes tipo 2 (T2DM). Material y métodos. Se incluyeron 150 mujeres con HTA autorreportada y sin T2DM, pareadas por edad con 300 mujeres sin diagnóstico de HTA y T2DM. Se entrevistaron a las mujeres sobre características de estilo de vida, sociodemográficas y clínicas. Los metabolitos urinarios de iAs se midieron por cromatografía líquida de alta resolución acoplada a espectrometría de masas con plasma acoplado inductivamente y se estimó la eficiencia de la metilación. Se utilizaron modelos de regresión logística no condicionada para evaluar las asociaciones. Resultados. Las concentraciones de arsénico urinario total menos arsenobetaína variaron de 0.57 a 303.29 µg/L, con una mediana de 12.90 µg/L. El modelo ajustado mostró una asociación negativa significativa entre la prevalencia de HTA y el porcentaje de ácido monometilarsónico (MMA) (RM T3 vs.T1: 0.52; IC95%: 0.31,0.86; p de tendencia: 0.03) y una asociación positiva significativa con el índice de metilación secundario (RM T3vs.T1: 1.94; IC95%: 1.17,3.22; p para la tendencia: ‹0.01). Conclusión. Se sugiere que el metabolismo del arsénico representó un papel esencial en estas asociaciones y se reconoce la necesidad de elucidar los mecanismos subyacentes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Exposure to arsenic: a major public healthconcern [Internet]. Geneva: WHO, 2010 [cited September 16, 2022].Available from: https://www.who.int/publications/i/item/WHO-CED-PHEEPE-19.4.1

  2. Tseng CH. A review on environmental factors regulating arsenic methylationin humans. Toxicol Appl Pharmacol. 2009;235(3):338-50. https://doi.org/10.1016/j.taap.2008.12.016

  3. Shen H, Niu Q, Xu M, Rui D, Xu S, Feng G, et al. Factors affecting arsenicmethylation in arsenic-exposed humans: a systematic review and metaanalysis.Int J Environ Res Public Health. 2016;13(2):205-22. https://doi.org/10.3390/ijerph13020205

  4. Chi-Hsin SJ, Harper C. Toxicological profile for arsenic. Atlanta: ATSDR,2007 [cited September 16, 2022]. Available from: https://stacks.cdc.gov/view/cdc/11481

  5. Kuo CC, Moon KA, Wang SL, Silbergeld E, Navas-Acien A. The associationof arsenic metabolism with cancer, cardiovascular disease, anddiabetes: a systematic review of the epidemiological evidence. EnvironHealth Perspect. 2017;125(8):087001-1-15. https://doi.org/10.1289/EHP577

  6. Gamboa-Loira B, Cebrián ME, López-Carrillo L. Physical activity, bodymass index and arsenic metabolism among Mexican women. Environ Res.2021;195:110869. https://doi.org/10.1016/j.envres.2021.110869

  7. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, StevensGA, et al. Worldwide trends in hypertension prevalence and progressin treatment and control from 1990 to 2019: a pooled analysis of 1201population-representative studies with 104 million participants. Lancet.2021;398(10304):957-80. https://doi.org/10.1016/S0140-6736(21)01330-1

  8. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E,Baddour LM, et al. Global burden of cardiovascular diseases and riskfactors, 1990-2019: update from the GBD 2019 Study. J Am Coll Cardiol.2020;76(25):2982-3021. https://doi.org/10.1016/j.jacc.2020.11.010

  9. Campos-Nonato I, Oviedo-Solís C, Vargas-Meza J, Ramírez-VillalobosD, Medina-García C, Gómez-Álvarez E, et al. Prevalencia, tratamiento ycontrol de la hipertensión arterial en adultos mexicanos: resultados dela Ensanut 2022. Salud Publica Mex. 2023;65(supl 1):s169-80. https://doi.org/10.21149/14779

  10. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension.Nat Rev Nephrol. 2020;16(4):223-37. https://doi.org/10.1038/s41581-019-0244-2

  11. Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. Arsenic exposureand hypertension: a systematic review. Environ Health Perspect.2012;120(4):494-500. https://doi.org/10.1289/ehp.1103988

  12. Islam MR, Khan I, Attia J, Hassan SMN, McEvoy M, D’Este C, et al. Associationbetween hypertension and chronic arsenic exposure in drinkingwater: a cross-sectional study in Bangladesh. Int J Environ Res PublicHealth. 2012;9(12):4522-36. https://doi.org/10.3390/ijerph9124522

  13. Li Y, Wang D, Li X, Zheng Q, Sun G. A Potential synergy betweenincomplete arsenic methylation capacity and demographic characteristicson the risk of hypertension: findings from a cross-sectional study in anarsenic-endemic area of Inner Mongolia, China. Int J Environ Res PublicHealth. 2015;12(4):3615. https://doi.org/10.3390/ijerph120403615

  14. Li X, Li B, Xi S, Zheng Q, Lv X, Sun G. Prolonged environmental exposureof arsenic through drinking water on the risk of hypertension andtype 2 diabetes. Environ Sci Pollut Res Int. 2013;20(11):8151-61. https://doi.org/10.1007/s11356-013-1768-9

  15. Cheng J, Li Y, He Q, Luo L, Zhang Y, Gao Y, et al. Essential hypertensionin patients exposed to high-arsenic exposed areas in western China:Genetic susceptibility and urinary arsenic metabolism characteristics.J Trace Elem Med Biol. 2021;67:126778-86. https://doi.org/10.1016/j.jtemb.2021.126778

  16. Wei B, Yu J, Wang J, Yang L, Li H, Kong C, et al. The relationships betweenarsenic methylation and both skin lesions and hypertension causedby chronic exposure to arsenic in drinking water. Environ Toxicol Pharmacol.2017;53(1):89-94. https://doi.org/10.1016/j.etap.2017.05.009

  17. Li X, Li B, Xi S, Zheng Q, Wang D, Sun G. Association of urinarymonomethylated arsenic concentration and risk of hypertension: a crosssectionalstudy from arsenic contaminated areas in northwestern China.Environ Health. 2013;12(1):1-10. https://doi.org/10.1186/1476-069X-12-37

  18. Huang YK, Tseng CH, Huang YL, Yang MH, Chen CJ, Hsueh YM. Arsenicmethylation capability and hypertension risk in subjects living in arseniasishyperendemicareas in southwestern Taiwan. Toxicol Appl Pharmacol.2007;218(2):135-42. https://doi.org/10.1016/j.taap.2006.10.022

  19. Mendez MA, González-Horta C, Sánchez-Ramírez B, Ballinas-CasarrubiasL, Cerón RH, Morales DV, et al. Chronic exposure to arsenic and markers ofcardiometabolic risk: a cross-sectional study in Chihuahua, Mexico. EnvironHealth Perspect. 2016;124(1):104-11. https://doi.org/10.1289/ehp.1408742

  20. Wang SL, Li WF, Chen CJ, Huang YL, Chen JW, Chang KH, et al.Hypertension incidence after tap-water implementation: a 13-yearfollow-up study in the arseniasis-endemic area of southwestern Taiwan. SciTotal Environ. 2011;409(21):4528-35. https://doi.org/10.1016/j.scitotenv.2011.07.058

  21. Spratlen MJ, Grau-Perez M, Best LG, Yracheta J, Lazo M, Vaidya D, etal. The association of arsenic exposure and arsenic metabolism with themetabolic syndrome and its individual components: prospective evidencefrom the strong heart family study. Am J Epidemiol. 2018;187(8):1598.https://doi.org/10.1093/aje/kwy048

  22. Sun D, Zhou T, Heianza Y, Li X, Fan M, Fonseca VA, et al. Type 2diabetes and hypertension: a study on bidirectional causality. Circ Res.2019;124(6):930. https://doi.org/10.1161/CIRCRESAHA.118.314487

  23. Colussi GL, Da Porto A, Cavarape A. Hypertension and type 2 diabetes:lights and shadows about causality. J Hum Hypertens. 2019;34(2):91-3.https://doi.org/10.1038/s41371-019-0268-x

  24. López-Carrillo L, Hernández-Ramírez RU, Gandolfi AJ, Ornelas-AguirreJM, Torres-Sánchez L, Cebrian ME. Arsenic methylation capacity is associatedwith breast cancer in Northern Mexico. Toxicol Appl Pharmacol.2014;280(1):53-9. https://doi.org/10.1016/j.taap.2014.07.013

  25. Holden B, Guice EA. An investigation of normal urine with a creatinineconcentration under the cutoff of 20 mg/dL for specimen validity testingin a toxicology laboratory. J Forensic Sci. 2014;59(3):806-10. https://doi.org/10.1111/1556-4029.12386

  26. Lin SY, Lee HH, Lee JF, Chen BH. Urine specimen validity test fordrug abuse testing in workplace and court settings. J Food Drug Anal.2018;26(1):380-4. https://doi.org/10.1016/j.jfda.2017.01.001

  27. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL.Urinary creatinine concentrations in the U.S. population: implicationsfor urinary biologic monitoring measurements. Environ Health Perspect.2005;113(2):192-200. https://doi.org/10.1289/ehp.7337

  28. Gilbert-Diamond D, Cottingham KL, Gruber JF, Punshon T, SayarathV, Gandolfi AJ, et al. Rice consumption contributes to arsenic exposure inUS women. Proc Natl Acad Sci U S A. 2011;108(51):20656-60. https://doi.org/10.1073/pnas.1109127108

  29. Barr DB, Landsittel D, Nishioka M, Thomas K, Curwin B, Raymer J,et al. A survey of laboratory and statistical issues related to farmworkerexposure studies. Environ Health Perspect. 2006;114(6):961-8. https://doi.org/10.1289/ehp.8528

  30. Blanco-Muñoz J, Morales MM, Lacasaña M, Aguilar-Garduño C, Bassol S,Cebrián ME. Exposure to organophosphate pesticides and male hormoneprofile in floriculturist of the state of Morelos, Mexico. Human Reproduction.2010;25(7):1787-95. https://doi.org/10.1093/humrep/deq082

  31. Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GT.Robust causal inference using directed acyclic graphs: the R package“dagitty.” Int J Epidemiol. 2016;45(6):1887-94. https://doi.org/10.1093/ije/dyw341

  32. Jones MR, Tellez-Plaza M, Sharrett AR, Guallar E, Navas-Acien A. Urinearsenic and hypertension in U.S. adults: the 2003-2008 NHANES. Epidemiology.2011;22(2):153. https://doi.org/10.1097/EDE.0b013e318207fdf2

  33. Zhao J, Li A, Mei Y, Zhou Q, Li Y, Li K, et al. The association of arsenicexposure with hypertension and blood pressure: a systematic review anddose-response meta-analysis. Environ Pollut. 2021;289:117914-27. https://doi.org/10.1016/j.envpol.2021.117914

  34. Kaufman JA, Mattison C, Fretts AM, Umans JG, Cole SA, VorugantiVS, et al. Arsenic, blood pressure, and hypertension in the Strong HeartFamily Study. Environ Res. 2021;195:110864-73. https://doi.org/10.1016/j.envres.2021.110864

  35. Vahter M, Åkesson A, Lidén C, Ceccatelli S, Berglund M. Genderdifferences in the disposition and toxicity of metals. Environ Res.2007;104(1):85-95. https://doi.org/10.1016/j.envres.2006.08.003

  36. Lindberg AL, Ekström EC, Nermell B, Rahman M, Lönnerdal B, PerssonLÅ, et al. Gender and age differences in the metabolism of inorganicarsenic in a highly exposed population in Bangladesh. Environ Res.2008;106(1):110-20. https://doi.org/10.1016/j.envres.2007.08.011

  37. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenic inducesoxidant stress and NF-kB activation in cultured aortic endothelial cells.Free Radic Biol Med. 1996;21(6):783-90. https://doi.org/10.1016/0891-5849(96)00174-8

  38. Straub AC, Stolz DB, Vin H, Ross MA, Soucy NV, Klei LR, et al.Low level arsenic promotes progressive inflammatory angiogenesisand liver blood vessel remodeling in mice. Toxicol Appl Pharmacol.2007;222(3):327-36. https://doi.org/10.1016/j.taap.2006.10.011

  39. Waghe P, Sarath TS, Gupta P, Kandasamy K, Choudhury S, KuttyHS, et al. Arsenic causes aortic dysfunction and systemic hypertensionin rats: augmentation of angiotensin II signaling. Chem Biol Interact.2015;237(1):104-14. https://doi.org/10.1016/j.cbi.2015.06.014

  40. Lim KM, Shin YS, Kang S, Noh JY, Kim K, Chung SM, et al. Potentiationof vasoconstriction and pressor response by low concentration of monomethylarsonousacid (MMA(III)). Toxicol Lett. 2011;205(3):250-6. https://doi.org/10.1016/j.toxlet.2011.06.008

  41. Bae ON, Lim EK, Lim KM, Noh JY, Chung SM, Lee MY, et al. Vascularsmooth muscle dysfunction induced by monomethylarsonous acid(MMA III): a contributing factor to arsenic-associated cardiovasculardiseases. Environ Res. 2008;108(3):300-8. https://doi.org/10.1016/j.envres.2008.06.012

  42. Lee MY, Lee YH, Lim KM, Chung SM, Bae ON, Kim H, et al. Inorganicarsenite potentiates vasoconstriction through calcium sensitization invascular smooth muscle. Environ Health Perspect. 2005;113(10):1330-5.https://doi.org/10.1289/ehp.8000

  43. Li B, Sun Y, Sun X, Wang Y, Li X, Kumagai Y, et al. Monomethylarsonousacid induced cytotoxicity and endothelial nitric oxide synthase phosphorylationin endothelial cells. Bull Environ Contam Toxicol. 2007;78(6):455-8.https://doi.org/10.1007/s00128-007-9178-7

  44. Pi J, Kumagai Y, Sun G, Yamauchi H, Yoshida T, Iso H, et al. Decreasedserum concentrations of nitric oxide metabolites among Chinese inan endemic area of chronic arsenic poisoning in inner Mongolia. FreeRadic Biol Med. 2000;28(7):1137-42. https://doi.org/10.1016/s0891-5849(00)00209-4

  45. Gutiérrez J, Rivera-Dommarco J, Shamah-Levy T, Villalpando-HernándezS, Franco A, Cuevas-Nasu L, et al. Encuesta Nacional de Salud y Nutrición2012. Resultados nacionales. Cuernavaca: Instituto Nacional de SaludPública, 2013 [cited January 21, 2024]. Available from: https://ensanut.insp.mx/encuestas/ensanut2012/doctos/informes/ENSANUT2012Resultados-Nacionales.pdf

  46. Alarcón-Herrera MT, Martin-Alarcon DA, Gutiérrez M, Reynoso-Cuevas L, Martín-Domínguez A, Olmos-Márquez MA, et al. Co-occurrence,possible origin, and health-risk assessment of arsenic and fluoride indrinking water sources in Mexico: Geographical data visualization. Sci TotalEnviron. 2020;698:134168. https://doi.org/10.1016/j.scitotenv.2019.134168

  47. Roberge J, O’Rourke MK, Meza-Montenegro MM, Gutiérrez-MillánLE, Burgess JL, Harris RB. Binational arsenic exposure survey: methodologyand estimated arsenic intake from drinking water and urinary arsenicconcentrations. Int J Environ Res Public Health. 2012;9(4):1051-67. https://doi.org/10.3390/ijerph9041051

  48. Concha G, Vogler G, Nermell B, Vahter M. Intra-individual variationin the metabolism of inorganic arsenic. Int Arch Occup Environ Health.2002;75(8):576-80. https://doi.org/10.1007/s00420-002-0361-1

  49. Scheer J, Findenig S, Goessler W, Francesconi KA, Howard B, UmansJG, et al. Arsenic species and selected metals in human urine: validationof HPLC/ICPMS and ICPMS procedures for a long-term populationbasedepidemiological study. Anal Methods. 2012;4(2):406. https://doi.org/10.1039/C2AY05638K




2020     |     www.medigraphic.com